|
|---|
|
|
|
|
|
b*****h
发帖数: 783 | | f**********g
发帖数: 2252 | 2 生鱼,could you say sth about ARNA and VICL?
Will send baozi later. Thanks.
发信人: yaokarl (大象，戒网中。。。), 信区: pennystock
标 题: 系统扫描股票
发信站: BBS 未名空间站 (Thu Oct 7 00:31:09 2010, 美东)
系统测试盈利率很高，可是扫出来的图形不太好看。只考虑RSI，没有考虑基本面。还
需要时间来检验，有兴趣的可以看看。另外，今天扫出来的大多数是卖出信号，提醒大
家减仓。YMYD
http://finviz.com/screener.ashx?v=341&t=VICL,LACO,CXDC,ARNA,CVO
【在 b*****h 的大作中提到】
: 还有人有吗？
| b*****h
发帖数: 783 | 3 arna就是超跌反弹，这周的risk相对还可以，下周就挺危险了。 找个高点卖就可以了
。
【在 f**********g 的大作中提到】
: 生鱼,could you say sth about ARNA and VICL?
: Will send baozi later. Thanks.
: 发信人: yaokarl (大象，戒网中。。。), 信区: pennystock
: 标 题: 系统扫描股票
: 发信站: BBS 未名空间站 (Thu Oct 7 00:31:09 2010, 美东)
: 系统测试盈利率很高，可是扫出来的图形不太好看。只考虑RSI，没有考虑基本面。还
: 需要时间来检验，有兴趣的可以看看。另外，今天扫出来的大多数是卖出信号，提醒大
: 家减仓。YMYD
: http://finviz.com/screener.ashx?v=341&t=VICL,LACO,CXDC,ARNA,CVO
| f**********g
发帖数: 2252 | 4 Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
Wednesday 10/06/2010 8:00 AM ET - Pr Newswire
Related Companies
Symbol Last %Chg
ARNA 1.84 4.51%
As of 10:13 AM ET 10/12/10
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today
upcoming lorcaserin presentations at Obesity 2010, the 28th Annual
Scientific Meeting of The Obesity Society, in San Diego, California.
Lorcaserin, which Arena discovered and developed, is intended for weight
management, including weight loss and maintenance of weight loss, in
patients who are obese (Body Mass Index, or BMI, >30) or patients who are
overweight (BMI >27) and have at least one weight-related co-morbid
condition.
"Obesity 2010 is an excellent scientific forum to present results from our
recently completed clinical study evaluating the effects of lorcaserin on
appetite, energy intake and energy expenditure," stated William R. Shanahan,
M.D., Arena's Senior Vice President and Chief Medical Officer. "We look
forward to presenting at this event, and to lorcaserin's October 22nd PDUFA
date."
The meeting schedule includes presentations of a lorcaserin mechanism of
action study conducted by Drs. Eric Ravussin, Leanne Redman, Corby Martin
and Steven Smith at the Pennington Biomedical Research Center in Baton Rouge
, Louisiana.
Saturday, October 9, 2010
Oral Abstract Presentation: Lorcaserin, a Novel 5-HT2C Receptor Agonist,
Causes Weight Loss Without Stimulating Energy Expenditure
Session Time: 4:45 p.m. - 6:15 p.m. Pacific Time (PT)
Sunday, October 10, 2010
Poster Presentation: Lorcaserin, a Selective 5-HT2C Receptor Agonist,
Reduces Energy Intake and Appetite
Session Time: The poster will be on display from 9:30 a.m. to 1:45 p.m. PT
and from 3:15 p.m. to 6:30 p.m. PT. Presenters will be available to discuss
the poster from 12:30 p.m. to 1:30 p.m. PT. | f**********g
发帖数: 2252 | 5 Arena Pharmaceuticals Investigated by Goldfarb Branham Law Firm LLP
Friday 10/08/2010 9:57 AM ET - Businesswire
Related Companies
Symbol Last %Chg
ARNA 1.84 4.55%
As of 10:14 AM ET 10/12/10
Goldfarb Branham LLP is investigating shareholder claims against officers
and directors of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) due to the
revelation that the FDA advisory panel voted against approval of an Arena
drug called Lorcaserin. Shareholders are encouraged to contact the firm at
877-583-2855 or h******[email protected] to learn about their rights.
"The Food and Drug Administration issued a document that questioned the
safety and efficacy of Arena's Lorcaserin drug," said securities attorney
Hamilton Lindley. "That FDA document revealed, among other things, that the
drug was associated with malignant tumors in rats. After this news and a
report that the FDA advisory panel reportedly rejected Lorcaserin due to
concerns with the potential safety problems, Arena stock has dropped 87
percent."
Goldfarb Branham LLP is investigating a derivative lawsuit against company
officers and directors for allowing this to occur. Derivative lawsuits often
lead to restored confidence in companies involved in financial scandal and
a resulting increase in shareholder value. Concerned shareholders who still
hold their shares are urged to contact attorney Hamilton Lindley at 877-583-
2855 or h******[email protected]. | f**********g
发帖数: 2252 | 6 3rd UPDATE: Abbott Halts Meridia Sales In US, Canada, Australia
Friday 10/08/2010 1:35 PM ET - Dow Jones News
Related Companies
Symbol Last %Chg
ABT 52.80 -0.02%
ARNA 1.82 3.43%
GSK 41.34 -0.24%
OREX 6.32 1.77%
RHHBY 35.24 -2.11%
As of 10:11 AM ET 10/12/10
(Adds detail, background.)
By Jennifer Corbett Dooren
Of DOW JONES NEWSWIRES
WASHINGTON (Dow Jones)--Abbott Laboratories (ABT) said Friday it was pulling
Meridia off the U.S., Canadian and Australian markets at the request of
health regulators on concerns the company's weight-loss drug increases the
risk of heart attacks and strokes.
"Meridia's continued availability is not justified when you compare the very
modest weight loss that people achieve on this drug to their risk of heart
attack or stroke," the Food and Drug Administration said.
The removal of Meridia from the U.S. market leaves just one prescription
weight loss product approved for long-term treatment: Roche Holding AG's (
ROG.VX, RHHBY) Xenical. An over-the-counter version of Xenical is available
from GlaxoSmithKline PLC. (GSK, GSK.LN).
The FDA is currently considering three other prescription weight-loss drugs,
but so far FDA panels have recommended against approving drugs from Vivus
Inc. (VVUS) and Arena Pharmaceuticals Inc. (ARNA). Orexigen Therapeutics Inc
. (OREX)'s proposed weight-loss treatment, Contrave, is expected to be
reviewed by an FDA panel in December.
In a statement, Abbott said it believed that Meridia "had a positive risk/
benefit profile in the approved patient population, but will comply with the
FDA's request." Meridia was removed from European markets earlier this year
.
Meridia was approved in the U.S. in 1997, the same year two diet drugs that
were part of the combination known as fen-phen were taken off the market.
Those drugs were linked to thousands of reports of heart-valve damage as
well as cases of a rare but often deadly lung disease.
Global sales of Meridia had once exceeded $350 million but have dropped amid
recent safety concerns. Abbott hasn't promoted the drug in the U.S. in the
past several years. Use of the Meridia has fallen from 1.3 million
prescriptions in 1998 to about 250,000 last year, according to the FDA.
An FDA memo outlining the agency's rationale for requesting Meridia's
removal from the market showed agency staff was united. The agency had been
divided on other high profile safety issues such as GlaxoSmithKline's
diabetes drug Avandia. Last month FDA decided to allow Avandia to remain on
the market with tight restrictions.
The FDA's decision on Meridia followed a split decision by an advisory panel
last month that met to discuss a clinical study conducted in about 10,000
patients with a history of cardiovascular problems. The study suggested
Meridia increased the risk of heart attack or stroke by about 16% compared
to placebo.
Eight members of the panel voted to recommend that the FDA withdraw Meridia
from the U.S. market, while six members said the product should remain on
the market with tougher warnings and only be sold as part of a restricted
distribution system. Two panel members voted to keep Meridia on the market
with a more prominent boxed warning.
Global sales of Meridia in the first nine months of 2010 were approximately
$80 million, one-quarter of it in the U.S.
Abbott also said it was having "ongoing discussions with regulatory
authorities in countries where [Meridia] is marketed and anticipates
concluding those discussions in the coming days."
Shares were up 0.5% at $52.83 in recent trading.
Separately, the FDA warned consumers Friday against using a product sold
over the Internet called Slimming Beauty Bitter Orange Slimming Capsules.
The agency said it found the product contains "excessive amounts" of
sibutramine, which is the active ingredient in Meridia. FDA said
siburtramine is not listed on Slimming Beauty's label.
-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.
c*****[email protected]
(Matt Jarzemsky contributed to this report.) | f**********g
发帖数: 2252 | 7 Thanks. Do u know VICL? Chart looks like ARNA but weaker, not dare to buy at
the bottom?
【在 b*****h 的大作中提到】
: arna就是超跌反弹，这周的risk相对还可以，下周就挺危险了。 找个高点卖就可以了
: 。
| f**********g
发帖数: 2252 | 8 Vical to manufacture plasmid DNA vaccines against HIV
Monday 10/11/2010 9:42 AM ET - Datamonitor
Related Companies
Symbol Last %Chg
VICL 2.20 -0.45%
As of 10:17 AM ET 10/12/10
Vical, a biopharmaceutical company, has agreed to manufacture plasmid DNA
vaccines against HIV under a $2.4 million contract with the IPPOX Foundation
, a collaborating institution for the Poxvirus Vaccine Regimen Design led by
the Centre Hospitalier Universitaire Vaudois under the auspices of the
collaboration for AIDS vaccine discovery.
The current project is investigating whether the second generation DNA/
poxvirus vaccine approach combined with immunization strategies can induce
increased and balanced Env, Gag, Pol and Nef HIV-1-specific T-cell responses
in humans.
Vical will produce individual plasmids encoding selected portions of the Env
and Gag antigens, and one plasmid encoding selected portions of the Pol and
Nef antigens. These plasmids will be combined and delivered as a single
vaccine. Delivery is expected to be completed in the fourth quarter of 2010.
at
【在 f**********g 的大作中提到】
: Thanks. Do u know VICL? Chart looks like ARNA but weaker, not dare to buy at
: the bottom?
| b*****h
发帖数: 783 | 9 sorry，不了解vicl。呵呵
at
【在 f**********g 的大作中提到】
: Thanks. Do u know VICL? Chart looks like ARNA but weaker, not dare to buy at
: the bottom?
| f**********g
发帖数: 2252 | 10 fangxuanling，您好：
您转给 biofish,现金(伪币):10,收取手续费:0.1
同时附加了如下留言给 biofish.
thanks
【在 b*****h 的大作中提到】
: arna就是超跌反弹，这周的risk相对还可以，下周就挺危险了。 找个高点卖就可以了
: 。
| | | b*****h
发帖数: 783 | 11 多谢包子。。
【在 f**********g 的大作中提到】
: fangxuanling，您好：
: 您转给 biofish,现金(伪币):10,收取手续费:0.1
: 同时附加了如下留言给 biofish.
: thanks
| w*******d
发帖数: 3714 | 12 昨天收到了某律师行寄过来的class action suit的信息信。。。 估计最后会以settle
告终吧？谁知道类似的先例一般啥结果？ | f**********g
发帖数: 2252 | 13 Me too, I got letters from arna and many other like COCO. I do not want
spend time for these law suits just throw the letters away. We take risks
when we buy stocks.
settle
【在 w*******d 的大作中提到】
: 昨天收到了某律师行寄过来的class action suit的信息信。。。 估计最后会以settle
: 告终吧？谁知道类似的先例一般啥结果？
| w*******d
发帖数: 3714 | 14 集体诉讼我们啥都不用干的啊，只要等着最后settle了，file claim领钱就可以了，哪
怕一股赔1毛，1000股也是100块呢，苍蝇肉也是肉。。。
【在 f**********g 的大作中提到】
: Me too, I got letters from arna and many other like COCO. I do not want
: spend time for these law suits just throw the letters away. We take risks
: when we buy stocks.
:
: settle
| f**********g
发帖数: 2252 | 15 It depends. What if u earn money from them?
【在 w*******d 的大作中提到】
: 集体诉讼我们啥都不用干的啊，只要等着最后settle了，file claim领钱就可以了，哪
: 怕一股赔1毛，1000股也是100块呢，苍蝇肉也是肉。。。
| b*****h
发帖数: 783 | 16 要厚道。。呵呵
【在 w*******d 的大作中提到】
: 集体诉讼我们啥都不用干的啊，只要等着最后settle了，file claim领钱就可以了，哪
: 怕一股赔1毛，1000股也是100块呢，苍蝇肉也是肉。。。
| n**2
发帖数: 630 | 17 想想你在水下的时候，MM啥时厚道过？！
【在 b*****h 的大作中提到】
: 要厚道。。呵呵
| w*******d
发帖数: 3714 | 18 我不知道最后会怎么settle，但如果我qualify，苍蝇肉也要吃一口啊。。。
【在 f**********g 的大作中提到】
: It depends. What if u earn money from them?
|
|
|
|
|
|
|
